On November 1, 2024, Director Christopher Causey sold 510 shares of United Therapeutics Corp (UTHR, Financial) at a price of $376.63 per share, as detailed in the SEC Filing. Following this transaction, the insider now owns 3,675 shares of the company.
United Therapeutics Corp, a biotechnology firm, focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Over the past year, Christopher Causey has engaged in multiple transactions, selling a total of 14,360 shares and purchasing none. This recent sale is part of a broader trend observed within the company, where there have been 109 insider sells and no insider buys over the past year.
The shares of United Therapeutics Corp were trading at $376.63 on the day of the sale, giving the company a market cap of approximately $16.822 billion. The price-earnings ratio of the stock stands at 16.55, which is lower than the industry median of 26.485.
According to the GF Value, the intrinsic value of United Therapeutics Corp is estimated at $326.43 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.15.
This valuation is based on historical trading multiples like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by GuruFocus for past returns and growth, and supplemented with future business performance estimates from Morningstar analysts.
The ongoing insider selling trend and the current valuation metrics provide critical data points for investors monitoring United Therapeutics Corp's stock performance and insider behaviors.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
